Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eupraxia PharmaceuticalsEPRX +0.90%34 EV-to-OCF is -8.82 as of Aug. 15, 2026. GuruFocus rates EPRX with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,410 Biotechnology companies, Eupraxia Pharmaceuticals ranks better than 69.08% on this metric.
The historical rank and industry rank for Eupraxia Pharmaceuticals's EV-to-OCF or its related term are showing as below:
EPRX'
s EV-to-OCF Range Over the Past 10 Years
Min: -8.87 Med: 0 Max: -8.87
Current: -8.87
During the past 9 years, the highest EV-to-OCF of Eupraxia Pharmaceuticals was -8.87. The lowest was -8.87. And the median was .
EPRX's EV-to-OCF is ranked better than 69.08% of 1410
companies
in the Biotechnology industry
Industry Median: -3.52
vs EPRX: -8.87
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eupraxia Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Eupraxia Pharmaceuticals's share price for today is $6.72.
Eupraxia Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Eupraxia Pharmaceuticals EV-to-OCF Related Terms
Eupraxia Pharmaceuticals EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Eupraxia Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eupraxia Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Eupraxia Pharmaceuticals's EV-to-OCF falls into.
Eupraxia Pharmaceuticals's current Enterprise Value is $330.68 Mil.
Eupraxia Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eupraxia Pharmaceuticals (EPRX) has a EV-to-OCF of -8.82 as of Aug. 15, 2026. According to the industry distribution chart, Eupraxia Pharmaceuticals ranks #436 out of 1410 companies in the Biotechnology industry, placing it in the top 30.9%.
Is Eupraxia Pharmaceuticals' EV-to-OCF too high?
Eupraxia Pharmaceuticals' current EV-to-OCF is -8.82. Based on the distribution chart, Eupraxia Pharmaceuticals ranks #436 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eupraxia Pharmaceuticals ranks #436 out of 1410 companies for EV-to-OCF. This puts Eupraxia Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Eupraxia Pharmaceuticals's current EV-to-OCF is -8.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (EPRX) has a current EV-to-OCF of -8.82. The current EV-to-OCF is -8.82. Eupraxia Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (EPRX), the current EV-to-OCF is -8.82 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
34GF Score
Get the complete analysis for EPRX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EPRX has been successfully added to your 
